Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), would like to invite interested shareholders and investors to a fun and informal “Fireside Chat” with the company's CEO, Ellen Donnelly, and members of the Abliva team, in Stockholm (28 September) and Lund (29 September).
After a long stretch of stringent travel restrictions and two-dimensional zoom presentations, we would like to invite Abliva shareholders and interested investors to an informal gathering to hear more about the Abliva strategy and direction directly from Ellen Donnelly (CEO) and the Abliva team. Ellen, an American, joined the company as CEO in February 2021 but has been unable to visit due to COVID restrictions. We hope you will join us in Stockholm or Lund at the end of the month to hear an update on the company and ask your most pressing questions. Seats are limited so please respond quickly to reserve your space.
Stockholm (center): 28 September, 5:00 – 6:00 p.m. CEST.
Lund: 29 September, 4:30 – 5.30 p.m. CEST.
Please respond to firstname.lastname@example.org to reserve your space. Meeting details will be provided after registration.